Mostaghimi Hesameddin, Mehdizadeh Ali Reza, Jahanbakhsh Mohammad, Dehghanian Amir Reza, Askari Ramin
Department of Biomedical Physics and Engineering, School of Medicine, Shiraz University of Medical Sciences, Shiraz; Advanced Health Technologies Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Biomedical Physics and Engineering, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
J Cancer Res Ther. 2017 Oct-Dec;13(6):930-935. doi: 10.4103/jcrt.JCRT_1224_16.
Previous studies have reported direct relationship between tumor reduction and its platinum concentration following platinum-based (Pt-based) chemotherapy. However, quantitative data of tumor platinum concentration have not yet been reported for the most common cancers.
Determination of tumor platinum concentration of breast, lung, prostate, and colorectal cancers after Pt-based chemotherapy; and evaluation of the influence of chemo drug type, chemotherapy regimen, and time lapse from last chemotherapy on tumor platinum concentration.
Tumor samples of patients with advanced breast, lung, prostate, and colorectal cancers undergone Pt-based chemotherapy were collected from pathology collection of various hospitals. The platinum concentration of each sample was measured by inductively coupled plasma optical emission spectrometry. The data were categorized by drug type, time lapse from last chemotherapy, and regimen type to evaluate their effects on platinum concentration.
ANOVA, Mann-Whitney U and Kruskal-Wallis tests were used.
Tumor platinum concentrations of breast, lung, prostate, and colorectal cancers were all obtained in the range of 1-10 μg/g tumor tissue. Large values of P (>0.05) indicate no significant differences between various chemo drug, regimen, and time groups.
In general, the platinum concentration was higher in prostate and lower in lung tumors. The type of Pt-based chemo drug, time lapse from the last chemotherapy, and concurrency of other antineoplastic agents administered with Pt-based chemo drugs had no significant effect on tumor platinum concentration.
先前的研究报道了铂类化疗后肿瘤缩小与其铂浓度之间的直接关系。然而，对于最常见的癌症，尚未有肿瘤铂浓度的定量数据报道。
测定铂类化疗后乳腺癌、肺癌、前列腺癌和结直肠癌的肿瘤铂浓度；并评估化疗药物类型、化疗方案以及距上次化疗的时间间隔对肿瘤铂浓度的影响。
从各医院病理样本库中收集接受铂类化疗的晚期乳腺癌、肺癌、前列腺癌和结直肠癌患者的肿瘤样本。通过电感耦合等离子体发射光谱法测量每个样本的铂浓度。数据按药物类型、距上次化疗的时间间隔和方案类型进行分类，以评估它们对铂浓度的影响。
采用方差分析、曼-惠特尼U检验和克鲁斯卡尔-沃利斯检验。
乳腺癌、肺癌、前列腺癌和结直肠癌的肿瘤铂浓度均在1 - 10μg/g肿瘤组织范围内。P值较大（>0.05）表明不同化疗药物、方案和时间组之间无显著差异。
总体而言，前列腺肿瘤中的铂浓度较高，而肺肿瘤中的铂浓度较低。铂类化疗药物的类型、距上次化疗的时间间隔以及与铂类化疗药物同时使用的其他抗肿瘤药物对肿瘤铂浓度无显著影响。
